Overview
Alpha‑mannosidosis (AM) is a rare, progressive lysosomal disorder with a broad and heterogeneous clinical phenotype that can evolve across the lifespan. Drawing on the 2024 Global Delphi Consensus Recommendations and other recent evidence, this activity focuses on practical, clinician‑oriented strategies for baseline and longitudinal assessment, use of enzyme replacement therapy and hematopoietic stem cell transplantation, monitoring treatment response and disease progression, and the coordination of interprofessional, multidisciplinary care essential for patient management.
This course is brought to you in partnership with our sister company freeCME. Clicking the Add to Cart button will take you to the freeCME website where you can access this course for FREE.
Goals and Learning Outcomes
Upon completion of this activity, participants should be better able to:
- Identify the characteristics and clinical presentation of alpha-mannosidosis that should prompt a referral to a specialist
- Develop patient-specific ERT treatment regimens that align with current best practices to achieve optimal patient outcomes
- Apply recommended strategies for incorporating HSCT, supportive care, and integrated team-based care for patients with alpha-mannosidosis
Faculty
Laura D. Buch, MSPAS, PA-C
Genetics Physician Associate
Greenwood Genetic Center
Greenville, South Carolina
Barbara K. Burton, MD
Professor of Pediatrics
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Course Details
FREECME2026-03-12
Accreditations
This course is being provided by a Relias LLC strategic partner. Consumption of this course will take place on the partners site and courses provided in this manner are not accredited by Relias LLC.